If you've been curious about semaglutide or tirzepatide, one question comes up before all the others: do I actually qualify? GLP-1 medications are prescribed based on your body mass index (BMI) and your overall health picture, not just a number on a scale. This post covers how clinicians decide and who these medications aren't right for.
This article is educational and isn't a substitute for personalized medical advice. Eligibility is always determined during a real clinical evaluation.
Who Qualifies for GLP-1 Weight Loss Medication?
The standard framework that guides most clinicians comes from FDA labeling for chronic weight management. GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition.
There are two ways to qualify:
- A BMI of 30 or above (the threshold for obesity), or
- A BMI of 27 to 29.9 (the overweight range) plus at least one weight-related health condition.
BMI is the starting point because it's the standard screening tool. Overweight and obesity are defined by body mass index (BMI), a measurement that uses your weight and height to estimate overweight and obesity. Patients in our practice often have nearly identical BMIs but very different health profiles. A thorough history matters more than any single number.
Which conditions count toward the BMI 27+ pathway?
If your BMI sits in the 27 to 29.9 range, a qualifying weight-related condition opens the door. Commonly recognized examples include cardiovascular conditions such as coronary heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference, or another obesity-related medical condition like sleep apnea.
Research consistently shows that risk rises as BMI climbs: the risk of obstructive sleep apnoea, type 2 diabetes, hip and knee osteoarthritis, and asthma increases significantly with increasing BMI. Treating obesity early, as a medical condition rather than a willpower problem, can pay off across the rest of your health.
Why Doctors Look Beyond BMI
BMI doesn't measure body composition, where you carry weight, or your metabolic health. A muscular person can have a "high" BMI without excess fat, and someone in the overweight range may already have several metabolic red flags. So the medical conversation includes more than height and weight.
We also factor in your history with weight. Many people arrive having tried, sincerely and repeatedly, to lose weight through diet and exercise alone. That history is clinically meaningful and helps establish why medical treatment is appropriate. If you're weighing the timing, see how it works.
How GLP-1 Medications Actually Work
GLP-1 (glucagon-like peptide-1) is a natural gut hormone, and these medications mimic it. GLP-1 receptor activation slows gastric emptying, inhibits the release of glucagon, and stimulates insulin production, thereby improving glucose homeostasis.
Two effects matter most for weight:
- Slowed digestion. By slowing gastric emptying, it takes longer for food to leave your stomach, which keeps you feeling full longer and tends to change how much you eat.
- Appetite signaling in the brain. GLP-1 receptor agonists also drive central appetite regulation: reduced hunger and increased satiety through hypothalamic pathways.
Together, the satiety effect reduces food intake, appetite, and hunger, and these combined effects often result in weight loss. This is why nutrition and protein intake matter during treatment. Read more on our medications page.
Who Should Not Take GLP-1 Medications
Qualifying also means ruling out reasons these drugs aren't safe for you. The clearest red lines come from the labeling. For most GLP-1 medications, the FDA lists two true contraindication categories: personal or family history of medullary thyroid carcinoma (MTC) or MEN2, and known serious hypersensitivity to the medication.
A few other situations call for caution. According to FDA guidance, GLP-1 medications are generally not recommended in pregnancy, because safety data are limited; with a prior history of pancreatitis, due to a risk of triggering inflammation of the pancreas; or with a history of medullary thyroid carcinoma or MEN2.
The FDA boxed warning says GLP-1 receptor agonists should not be used in patients with MTC history or MEN2, and this warning exists because of rodent toxicology studies. A family history of papillary, follicular, or Hürthle cell thyroid cancer is not a contraindication. A careful clinical review sorts out nuances like this.
Is It Right for You?
Meeting the BMI threshold doesn't automatically mean a GLP-1 is the best choice. Missing it doesn't always close the door, since oral options and other tools exist. Our care is led by **Dr.
Tran Le, MD, DABOM**, triple board-certified in Obesity Medicine, Addiction Medicine, and Occupational and Environmental Medicine. Every plan starts with a real evaluation of your history, labs where appropriate, and goals.
For Texas or Utah patients, this all happens online. Our memberships keep it simple: all-inclusive compounded semaglutide or tirzepatide with the medication included, plus an à la carte plan for brand-name GLP-1s. Compare the details on our pricing page. Compounded medications are not FDA-approved.
Frequently Asked Questions
What BMI do you need to qualify for semaglutide or tirzepatide?
Generally a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea. A clinician confirms eligibility during your visit.
Can I qualify if my BMI is under 27?
Usually not for weight management, because safety and effectiveness data in that range are limited and the risk-benefit balance shifts. Your provider can talk through alternatives.
Does a family history of thyroid cancer disqualify me?
It depends on the type. A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication, while more common thyroid cancers generally are not. This is reviewed carefully before any prescription.
Ready to Find Out If You Qualify?
If you're in Texas or Utah, start your consultation here for a physician-led evaluation.